BR112016024103A2 - promotor do cmv humano, ácido nucleico, método de produção de polipeptídeos, uso de um promotor e célula - Google Patents

promotor do cmv humano, ácido nucleico, método de produção de polipeptídeos, uso de um promotor e célula

Info

Publication number
BR112016024103A2
BR112016024103A2 BR112016024103-7A BR112016024103A BR112016024103A2 BR 112016024103 A2 BR112016024103 A2 BR 112016024103A2 BR 112016024103 A BR112016024103 A BR 112016024103A BR 112016024103 A2 BR112016024103 A2 BR 112016024103A2
Authority
BR
Brazil
Prior art keywords
promoter
polypeptide production
nucleic acid
human cmv
cell
Prior art date
Application number
BR112016024103-7A
Other languages
English (en)
Other versions
BR112016024103B1 (pt
Inventor
Goepfert Ulrich
MORITZ Benjamin
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of BR112016024103A2 publication Critical patent/BR112016024103A2/pt
Publication of BR112016024103B1 publication Critical patent/BR112016024103B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção refere-se a um promotor que possui a sequência de ácidos nucleicos de seq id nº 2 ou seq id nº 3, que é um promotor/intensificador inicial imediato importante do cmv humano (hcmv-mie) com mutação de ponto c para g na posição -41 e/ou -179 com relação ao local de início da transcrição. este novo promotor é especialmente útil para a produção de polipeptídeos em larga escala, pois exibe silenciamento reduzido do promotor e produção aprimorada de polipeptídeos.
BR112016024103-7A 2014-05-19 2015-05-18 Promotor do cmv humano, ácido nucleico, método de produção de polipeptídeos e uso de um promotor BR112016024103B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14168901 2014-05-19
EP14168901.8 2014-05-19
EP14191705.4 2014-11-04
EP14191705 2014-11-04
PCT/EP2015/060880 WO2015177084A1 (en) 2014-05-19 2015-05-18 Method for production of polypeptides

Publications (2)

Publication Number Publication Date
BR112016024103A2 true BR112016024103A2 (pt) 2018-01-23
BR112016024103B1 BR112016024103B1 (pt) 2022-12-27

Family

ID=53199978

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016024103-7A BR112016024103B1 (pt) 2014-05-19 2015-05-18 Promotor do cmv humano, ácido nucleico, método de produção de polipeptídeos e uso de um promotor

Country Status (16)

Country Link
US (2) US10329595B2 (pt)
EP (1) EP3146057B1 (pt)
JP (1) JP6661549B2 (pt)
KR (1) KR102337049B1 (pt)
CN (1) CN106255757B (pt)
BR (1) BR112016024103B1 (pt)
CA (1) CA2943719A1 (pt)
ES (1) ES2821940T3 (pt)
HK (1) HK1232253A1 (pt)
HR (1) HRP20201468T1 (pt)
MX (1) MX2016014473A (pt)
PL (1) PL3146057T3 (pt)
RU (1) RU2699715C2 (pt)
SG (1) SG11201609639VA (pt)
SI (1) SI3146057T1 (pt)
WO (1) WO2015177084A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420653T1 (de) * 2001-02-23 2009-01-15 Scripps Research Inst Von tryptophanyl-trna-synthetase stammende polypeptide zur regulierung der angiogenese
CN100429315C (zh) * 2003-03-11 2008-10-29 雪兰诺实验室有限公司 含有mcmv ie2启动子的表达载体
JP5351041B2 (ja) * 2006-12-15 2013-11-27 リボバックス バイオテクノロジーズ ソシエテ アノニム ヒトサイトメガロウィルス（ｈｍｃｖ）に対する抗体
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
WO2011128377A1 (en) * 2010-04-14 2011-10-20 F. Hoffmann-La Roche Ag Method for the selection of a long-term producing cell
EP2655636B1 (en) * 2010-12-24 2015-04-22 Agency For Science, Technology And Research Modified cmv promoters that are resistant to gene silencing
WO2012099540A1 (en) * 2011-01-17 2012-07-26 Agency For Science, Technology And Research Cmv promoter variants

Also Published As

Publication number Publication date
PL3146057T3 (pl) 2020-12-14
US20170067087A1 (en) 2017-03-09
WO2015177084A1 (en) 2015-11-26
KR20170003699A (ko) 2017-01-09
RU2699715C2 (ru) 2019-09-09
RU2016149411A (ru) 2018-06-20
KR102337049B1 (ko) 2021-12-08
RU2016149411A3 (pt) 2019-04-25
HK1232253A1 (zh) 2018-01-05
HRP20201468T1 (hr) 2020-12-11
EP3146057A1 (en) 2017-03-29
ES2821940T3 (es) 2021-04-28
US20190360014A1 (en) 2019-11-28
CA2943719A1 (en) 2015-11-26
MX2016014473A (es) 2017-01-23
CN106255757B (zh) 2020-08-11
EP3146057B1 (en) 2020-07-29
SG11201609639VA (en) 2016-12-29
CN106255757A (zh) 2016-12-21
BR112016024103B1 (pt) 2022-12-27
JP6661549B2 (ja) 2020-03-11
US10329595B2 (en) 2019-06-25
SI3146057T1 (sl) 2020-11-30
JP2017515492A (ja) 2017-06-15

Similar Documents

Publication Publication Date Title
BR112018007017A2 (pt) polipeptídeos
MX2016017296A (es) Sintasa del acido cannabicromenico proveniente de cannabis sativa.
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
ES2743232T3 (es) Métodos para la activación o eliminación controlada de células terapéuticas
CL2016003277A1 (es) Métodos para preparar análogos de nucleótido sustituidos
BR112018011059A2 (pt) synp161, um promotor para a expressão específica de genes em fotoreceptores de haste
BR122021004223A8 (pt) Molécula de anticorpo, composição, sequência de nucleotídeo, vetor, molécula de anticorpo e uso de uma molécula de anticorpo
NI201600028A (es) Polipéptido para la escisión hidrolítica de la zearalenona y/o derivados de la zearalenona, polinucleótido aislado de la misma y poliéptido que contiene aditivo, uso y procedimiento de los mismos.
BR112014008152A2 (pt) método para produção de uma proteina de interesse cultivando uma linhagem celular eucariótica recombinante compreendendo uma construção de expressão compreendendo um promotor regulável e uma molécula de ácido nucleico que codifica uma poi sob o controle transcricional de tal promotor
EA201790884A8 (ru) 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
BR112017021289A2 (pt) anticorpos anti-c1s humanizados e métodos de uso dos mesmos
CL2018000164A1 (es) Vector recombinante del virus orf.
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
EA201790881A8 (ru) 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
EA201790885A1 (ru) 6α-АЛКИЛ-6,7-ДИОНОВЫЕ СТЕРОИДЫ В КАЧЕСТВЕ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ ДЛЯ ПОЛУЧЕНИЯ СТЕРОИДНЫХ МОДУЛЯТОРОВ FXR
BR112018077358A2 (pt) tagatose-6-fosfato fosfatase termoestável inovadora e um método para produzir tagatose com o uso da mesma
WO2015196150A3 (en) Mutations that confer genetic stability to additional genes in influenza viruses
EA201790879A1 (ru) 6-альфа-алкил-3,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
BR112017003733A2 (pt) ?micro-organismo recombinante que produz alcenos a partir de acetil-coa?.
UA117935C2 (uk) Спосіб одержання l-амінокислот
BR112018070249A2 (pt) sistema promotor de u6 modificada para expressão específica de tecido
BR112019007343A2 (pt) sequência de nucleotídeos expressando uma proteína de ancoragem de exossomo para uso como vacina
BR112017027729A2 (pt) indução de expressão de gene com o uso de uma mistura de açúcar de concentração alta
BR112018003778A2 (pt) animal transgênico para produção de anticorpos que apresenta uma cadeia leve comum
BR112019005600A2 (pt) promotor de planta para expressão de transgene

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/05/2015, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 9A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2775 DE 12-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.